As Covid drug cash dwindles, Vigonvita targets new remedies
A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Innogen Pharma jostles for a slice of the weight-loss market
